HIV Seropositivity: Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).HIV Seroprevalence: Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV SEROPOSITIVITY).HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).Substance Abuse, Intravenous: Abuse, overuse, or misuse of a substance by its injection into a vein.Sexual Behavior: Sexual activities of humans.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Seroepidemiologic Studies: EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Chlamydophila pneumoniae: A species of CHLAMYDOPHILA that causes acute respiratory infection, especially atypical pneumonia, in humans, horses, and koalas.Chlamydophila Infections: Infections with bacteria of the genus CHLAMYDOPHILA.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Serologic Tests: Diagnostic procedures involving immunoglobulin reactions.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.HIV Seronegativity: Immune status consisting of non-production of HIV antibodies, as determined by various serological tests.Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.Helicobacter pylori: A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405).Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.Toxocariasis: Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.Antibodies, Protozoan: Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.Toxoplasmosis: The acquired form of infection by Toxoplasma gondii in animals and man.Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.Cross-Sectional Studies: Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.Toxocara: A genus of ascarid nematodes commonly parasitic in the intestines of cats and dogs.Herpesvirus 2, Human: A species of SIMPLEXVIRUS associated with genital infections (HERPES GENITALIS). It is transmitted by sexual intercourse and close personal contact.AIDS Serodiagnosis: Immunologic tests for identification of HIV (HTLV-III/LAV) antibodies. They include assays for HIV SEROPOSITIVITY and HIV SERONEGATIVITY that have been developed for screening persons carrying the viral antibody from patients with overt symptoms of AIDS or AIDS-RELATED COMPLEX.HIV-1: The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.Blood DonorsHepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.Neospora: A genus of protozoan parasites of the subclass COCCIDIA. Its species are parasitic in dogs, cattle, goats, and sheep, among others. N. caninum, a species that mainly infects dogs, is intracellular in neural and other cells of the body, multiplies by endodyogeny, has no parasitophorous vacuole, and has numerous rhoptries. It is known to cause lesions in many tissues, especially the brain and spinal cord as well as abortion in the expectant mother.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Papillomavirus Infections: Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.Rural Population: The inhabitants of rural areas or of small towns classified as rural.Syphilis: A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.Herpes Genitalis: Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.Cytomegalovirus: A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.Toxoplasma: A genus of protozoa parasitic to birds and mammals. T. gondii is one of the most common infectious pathogenic animal parasites of man.Immunoglobulin A: Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.BrazilHomosexuality: The sexual attraction or relationship between members of the same SEX.

*  Chemotherapy for Lung Cancer in HIV-positive Patients - Full Text View - ClinicalTrials.gov

HIV Seropositivity. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung Diseases. Respiratory ... HIV seropositivity (previous or inaugural), irrespective of CD4 count or viral load ... HIV Infections. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus Diseases. Sexually Transmitted ... Chemotherapy for Lung Cancer in HIV-positive Patients (CHIVA). This study has been completed. ...
https://clinicaltrials.gov/show/NCT01296113

*  Chemotherapy for Lung Cancer in HIV-positive Patients - Full Text View - ClinicalTrials.gov

HIV Seropositivity. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung Diseases. Respiratory ... HIV seropositivity (previous or inaugural), irrespective of CD4 count or viral load ... HIV Infections. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus Diseases. Sexually Transmitted ... Chemotherapy for Lung Cancer in HIV-positive Patients (CHIVA). This study is ongoing, but not recruiting participants. ...
https://clinicaltrials.gov/show/NCT01296113?order=11

*  Abstract | Prevalence of HIV seropositivity in children with chronic diarrhea

Prevalence of HIV seropositivity in children with chronic diarrhea Abstract. ... Prevalence of HIV seropositivity in children with chronic diarrhea. Abstract. The present study was conducted in children and ... We conclude that prevalence of HIV seropositivity is low in chronic diarrhea cases in this part of the country. ... All samples were subjected to initial screening by the ELISA based test for detection of HIV antibodies. The second test used ...
https://omicsonline.org/scholarly-articles/abstracts/prevalence-of-hiv-seropositivity-in-children-with-chronic-diarrhea-1446.html

*  HIV seropositivity in a Burn Center's population. | Base documentaire | BDSP

In the patient, HIV slows wound healing and increases the complications seen with burns. For the treating team, HIV is a hazard ... HIV infection in a patient with burn injuries complicates the care of both the patient and the treating burn team. ... HIV seropositivity in a Burn Center's population. R f. 164694 Article, Communication - En anglais ... HIV infection in a patient with burn injuries complicates the care of both the patient and the treating burn team. ...
bdsp.ehesp.fr/Base/164694/

*  A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management...

HIV seropositivity. *Biopsy diagnosis of a CD20+ diffuse large B-cell lymphoma or variants (including mediastinal (thymic) ... MedlinePlus related topics: HIV/AIDS Lymphoma Genetic and Rare Diseases Information Center resources: Lymphosarcoma B-cell ... HIV Infections. Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related. Neoplasms by Histologic Type. Neoplasms. ... Lymphoma, AIDS Related HIV Infections Drug: R-EPOCH and cART Phase 2 ...
https://clinicaltrials.gov/show/NCT00799136?order=57

*  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells - Full Text View - ClinicalTrials...

HIV seropositivity. *Diagnosis of Fanconi's anemia, Severe Combined Immunodeficiency (SCID). *Positive pregnancy test (For ...
https://clinicaltrials.gov/ct2/show/NCT00730314?recr=Open&cond="Speech Disorders"&rank=14

*  A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate ...

HIV seropositivity.. *Mucocutaneous herpes simplex virus (HSV) infection confirmed by previous viral culture and persisting ... HIV Infections. Herpes Simplex. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus Diseases. Sexually ...
https://clinicaltrials.gov/ct2/show/study/NCT00002116?view=record

*  Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients - Full Text View -...

HIV-1. Treatment simplification. Lopinavir/ritonavir. Treatment Experienced. HIV Seropositivity. Additional relevant MeSH terms ... HIV Protease Inhibitors. Protease Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of Pharmacological Action. Anti-HIV ... Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14;292(2): ... Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients (KALESOLO). This ...
https://clinicaltrials.gov/show/NCT00140751?order=86

*  A Study of Immune System Activity in Healthy Adults - Full Text View - ClinicalTrials.gov

HIV Seropositivity. Immune System. CD4-Positive T-Lymphocytes. HIV Seronegativity. Antigens, CD. ... Numbers of phenotypically naive CD4+ cells (CD45RA+/CD62L+) are compared between healthy, HIV-seronegative volunteers and HIV- ... HIV also affects immune system activity. The results from this study, using healthy volunteers, will be compared to those in ... Have HIV infection.. *Have a serious infection or other serious medical illness that requires treatment and/or hospitalization ...
https://clinicaltrials.gov/show/NCT00014053?order=23

*  Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+ - Full Text View - ClinicalTrials.gov

HIV Seropositivity. HIV Infections. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus Diseases. ... HIV Seropositivity Other: ARV's + Placebo Drug: Naltrexone Drug: Naltrexone + ARV's Phase 2 ... In the vast majority of those infected with HIV virus who are untreated, there is deterioration in immune health over a period ... Due to toxicity of current ARV drugs and need for special medical management young HIV infected children are largely neglected ...
https://clinicaltrials.gov/show/NCT01174914?order=191

*  The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients - Full Text View -...

HIV seropositivity.. *Mean CD4 count ,= 100 cells/mm3.. *External anogenital condyloma acuminatum confirmed by biopsy, present ... The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients. This study has been ... HIV Infections. Acquired Immunodeficiency Syndrome. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus ... A phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. Conf ...
https://clinicaltrials.gov/ct2/show/study/NCT00002327?view=record

*  Medical Marijuana Use in HIV+ Patients Prospective Cohort Study - Full Text View - ClinicalTrials.gov

HIV Seropositivity. Marijuana Abuse. HIV Infections. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. ...
https://clinicaltrials.gov/show/NCT01536899?order=586

*  Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission - Full Text View - ClinicalTrials.gov

HIV Infections. Sexually Transmitted Diseases. HIV Seropositivity. Lentivirus Infections. Retroviridae Infections. RNA Virus ... HIV Infections AIDS Sexually Transmitted Diseases HIV Seroconversion Drug: Carraguard (PC-515) Phase 3 ... HIV negative and agree to be tested for HIV and told their results at all visits during the study ... HIV. AIDS. STIs. STDs. Efficacy. HSV. Women. South Africa. seroconversion. condom. safe-sex. vaginal intercourse. prevention. ...
https://clinicaltrials.gov/show/NCT00213083?order=76

*  PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD) - Full...

HIV Infections. Dementia. Alzheimer Disease. Brain Diseases. HIV Seropositivity. AIDS Dementia Complex. Lentivirus Infections. ... HIV-Dementia. Brain. PET. PBR28. MCMD. HIV Positive. HIV Dementia. AIDS Related Dementia. Minor Cognitive Motor Disorder. ... HIV-Dementia HIV-Associated Cognitive Motor Complex AIDS Encephalopathy AIDS Dementia Complex AIDS-Related Dementia Complex HIV ... HIV-seropositive based on ELISA and Western blot (except the HIV-seronegative subjects, who will have ELISA screening). ...
https://clinicaltrials.gov/show/NCT00459693

*  GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When...

HIV Infections. HIV Seropositivity. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus Diseases. ... HIV Protease Inhibitors. Protease Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of Pharmacological Action. Anti-HIV ... HIV. AIDS. Immunodeficiency Virus, Human. Females. Women. PREZISTA. darunavir. TMC114. Protease Inhibitor. ... Number of Viral Load (VL) , 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex [ Time Frame: ...
https://clinicaltrials.gov/show/NCT00381303?order=53

*  Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients - Full Text View -...

HIV-1. Treatment simplification. Lopinavir/ritonavir. Treatment Experienced. HIV Seropositivity. Additional relevant MeSH terms ... HIV Protease Inhibitors. Protease Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of Pharmacological Action. Anti-HIV ... Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14;292(2): ... HIV Infections. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus Diseases. Sexually Transmitted ...
https://clinicaltrials.gov/ct2/show/study/NCT00140751?view=record

*  A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV...

HIV Infections. Retinitis. Cytomegalovirus Retinitis. HIV Seropositivity. Lentivirus Infections. Retroviridae Infections. RNA ... Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Analgesics, Non-Narcotic. Analgesics. ... A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV ... A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV ...
https://clinicaltrials.gov/show/NCT00002321?order=3

*  Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults - Full Text View - ClinicalTrials.gov

HIV Seropositivity. Vibrio Infections. Signs and Symptoms, Digestive. Signs and Symptoms. Gram-Negative Bacterial Infections. ... Mean HIV viral load (copies/ml) increases, with CholeraGarde® or placebo [ Time Frame: relative to baseline, at 7, 30, and 90 ... HIV-seropositive, non-pregnant adults, aged 18 - 45 years old who have been on standard highly active antiretroviral therapy ( ... Male and female HIV seropositive adults aged 18 to 45 years old who have given the written informed consent. ...
https://clinicaltrials.gov/show/NCT00741637

*  Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia - Full Text View...

No HIV seropositivity. *No allergy to eggs. PRIOR CONCURRENT THERAPY:. *No previous vaccination with vaccinia ...
https://clinicaltrials.gov/ct2/show/NCT00788164?recr=Open&cond="Uterine Cervical Dysplasia"&rank=15

*  How to join - British Army Website

HIV seropositivity / AIDS.. Being a carrier of hepatitis B or hepatitis C.. Past history of leukaemia or malignant lymphoma. ...
army.mod.uk/join/38416.aspx

*  Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid...

Human immunodeficiency virus (HIV) seropositivity. *Fungal infections with radiographic progression after receipt of ...
https://clinicaltrials.gov/ct2/show/NCT00045435?cond="Acute monoblastic leukemia"&rank=10

*  Evaluation of Patients Who Have Not Had Success With Zidovudine - Full Text View - ClinicalTrials.gov

Documented HIV-seropositivity.. *CD4 count 100 - 300 cells/mm3.. *Prior continuous AZT dose = or , 300 mg/day for 1 year or ... HIV Infections. Lentivirus Infections. Retroviridae Infections. RNA Virus Infections. Virus Diseases. Sexually Transmitted ... High-grade resistance to AZT has been detected in HIV isolates from approximately 25 percent of individuals with AIDS who ... High-grade resistance to AZT has been detected in HIV isolates from approximately 25 percent of individuals with AIDS who ...
https://clinicaltrials.gov/show/NCT00001025?order=193

*  Evolution of nutritional status of infants infected with the human immunodeficiency virus.

There are today only a limited number of studies defining growth parameters and nutritional status for HIV children. OBJECTIVE ... HIV Seropositivity. Humans. Infant. Infant, Newborn. Longitudinal Studies. Male. Nutritional Status*. Pregnancy. Pregnancy ... PARTICIPANTS: One hundred and twenty-four children born to HIV infected mothers were evaluated from birth until the age of two ... CONTEXT: There are today only a limited number of studies defining growth parameters and nutritional status for HIV children. ...
biomedsearch.com/nih/Evolution-nutritional-status-infants-infected/11018849.html

*  Stefan Mauss

anti hiv agents*carnitine*methadone*interferon alfa 2b*carbamates*hiv seropositivity*narcotics*aids related opportunistic ... hiv wasting syndrome*ribavirin*combination drug therapy*hiv infections*lipodystrophy*chronic hepatitis c*polyethylene glycols* ... HIV Med 2:59-60. 2001. *. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. Stefan ... HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?. S Mauss. Center for HIV and Hepatogastroenterology ...
https://labome.org/expert/mauss/stefan-mauss-292932.html

*  Parakoch: 2011

HCMV seropositivity as well as higher amounts of viral DNA, in general, was seen to be correlated with the high blood pressure ... Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy (5000 people in the US) ... HIV(7,8) and Epstein-Barr virus (9), hematological cancersincluding CLL and acute myelocytic leukemias, exposureto fungal ... Harvey Alter Health Care System Hemispherx Hemolytic Uremic Syndrome Herpesviridae High Blood Pressure Historic Outbreaks HIV ...
parakoch.blogspot.de/2011/

HIV-positive people: HIV-positive people are people who have the human immunodeficiency virus HIV, the agent of the currently incurable disease AIDS.Management of HIV/AIDS: The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs in an attempt to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle.QRISK: QRISK2 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial fibrillation, diabetes mellitus, and antihypertensive treatment.Seroprevalence: Seroprevalence is the number of persons in a population who test positive for a specific disease based on serology (blood serum) specimens; often presented as a percent of the total specimens tested or as a proportion per 100,000 persons tested. As positively identifying the occurrence of disease is usually based upon the presence of antibodies for that disease (especially with viral infections such as Herpes Simplex and HIV), this number is not significant if the specificity of the antibody is low.Chlamydophila pneumoniaeCD4 immunoadhesin: CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region.Eva Engvall: Eva Engvall, born 1940, is one of the scientists who invented ELISA in 1971.Eva Engvall, The Scientist 1995, 9(18):8CagA: Helicobacter pylori virulence factor CagA (cytotoxin-associated gene A) is a 120–145kDa protein encoded on the 40kb cag pathogenicity island (PAI). H.Toxocariasis: (ILDS B83.01)Cytomegalic inclusion body disease: Cytomegalic inclusion body disease (CIBD) is a series of signs and symptoms caused by cytomegalovirus infection, toxoplasmosis or other rare infections such as herpes or rubella viruses. It can produce massive calcification of the central nervous system, and often the kidneys.Adult-onset immunodeficiency syndrome: Adult-onset immunodeficiency syndrome is a provisional name for a newly diagnosed immunodeficiency illness. The name is proposed in the first public study to identify the syndrome.Vpx: Vpx is a virion-associated protein encoded by human immunodeficiency virus type 2 HIV-2 and most simian immunodeficiency virus (SIV) strains, but that is absent from HIV-1. It is similar in structure to the protein Vpr that is carried by SIV and HIV-2 as well as HIV-1.World Blood Donor Day: Every year on 14 June, countries around the world celebrate World Blood Donor Day (WBDD). The event, established in 2004, serves to raise awareness of the need for safe blood and blood products, and to thank blood donors for their voluntary, life-saving gifts of blood.List of people with hepatitis C: The infectious disease hepatitis C is caused by the hepatitis C virus (HCV), which affects the liver and is transmitted by blood-to-blood contact, or by exposure to another person's infected blood. The infection is often asymptomatic, but chronic infection can cause inflammation of the liver (chronic hepatitis).Nested case-control study: A nested case control (NCC) study is a variation of a case-control study in which only a subset of controls from the cohort are compared to the incident cases. In a case-cohort study, all incident cases in the cohort are compared to a random subset of participants who do not develop the disease of interest.History of syphilis: The history of syphilis has been well studied, but the exact origin of syphilis is unknown. There are two primary hypotheses: one proposes that syphilis was carried to Europe from the Americas by the crew of Christopher Columbus, the other proposes that syphilis previously existed in Europe but went unrecognized.RegavirumabSAG1 protein domain: In molecular biology, the SAG1 protein domain is an example of a group of glycosylphosphatidylinositol (GPI)-linked proteins named SRSs (SAG1 related sequence). SAG1 is found on the surface of a protozoan parasite Toxoplasma gondii.University of CampinasPrescott Townsend: Prescott Townsend (June 24, 1894 – May 23, 1973) was an American gay rights activist.

(1/3131) Tuberculous meningitis in South African urban adults.

We retrospectively reviewed 56 adults with culture-proven tuberculous meningitis (TBM), investigating clinical signs, cerebrospinal fluid (CSF) findings and outcome. There were 50 patients, aged 18-59 years, 39 with and 11 without human immunodeficiency virus (HIV) infection. Six were aged 60 years or older. Neurological signs of TBM in 18-59-year-olds were unaffected by HIV serostatus while, compared to those > or = 60 years of age, there were more patients with meningism (86.0% vs. 33.3%; p = 0.011) and fewer with seizures (12.0% vs. 50.0%; p = 0.046). The HIV-infected 18-59-year-olds had significantly more extrameningeal tuberculosis compared to the non-HIV-infected (76.9% vs. 9.1%; p = 0.0001) and 23.1% had 'breakthrough' TBM. CSF analysis revealed 12 patients (21.4%) with acellular fluid (more common in those > or = 60 years of age, p = 0.016), of whom three had completely normal CSF. A neutrophil predominance was found in 22 patients (39.3%). Only three patients (5.4%) had a positive CSF smear for acid-fast bacilli. In-hospital mortality occurred in 39 patients (69.1%), was similar in all study groups, and was not related to neurological stage. The diagnosis of TBM can be masked by lack of meningism in the elderly and by atypical CSF findings.  (+info)

(2/3131) Coalescent estimates of HIV-1 generation time in vivo.

The generation time of HIV Type 1 (HIV-1) in vivo has previously been estimated using a mathematical model of viral dynamics and was found to be on the order of one to two days per generation. Here, we describe a new method based on coalescence theory that allows the estimate of generation times to be derived by using nucleotide sequence data and a reconstructed genealogy of sequences obtained over time. The method is applied to sequences obtained from a long-term nonprogressing individual at five sampling occasions. The estimate of viral generation time using the coalescent method is 1.2 days per generation and is close to that obtained by mathematical modeling (1.8 days per generation), thus strengthening confidence in estimates of a short viral generation time. Apart from the estimation of relevant parameters relating to viral dynamics, coalescent modeling also allows us to simulate the evolutionary behavior of samples of sequences obtained over time.  (+info)

(3/3131) Cytokine profile induced by Cryptosporidium antigen in peripheral blood mononuclear cells from immunocompetent and immunosuppressed persons with cryptosporidiosis.

The proliferative response of peripheral blood mononuclear cells (PBMC) to a crude extract from Cryptosporidium parvum (CCE) was studied in persons who acquired cryptosporidiosis in the same outbreak (15 immunocompetent subjects with prior cryptosporidiosis and 22 human immunodeficiency virus [HIV]-positive persons with various levels of immunosuppression and active cryptosporidiosis) and in individual patients (8 HIV-positive patients with active cryptosporidiosis and 15 HIV-positive persons without history of cryptosporidiosis). PBMC from HIV-positive persons showed less proliferation to CCE and mitogens than did PBMC from immunocompetent subjects with prior cryptosporidiosis, independent of CD4 cell count. In immunocompetent subjects, cytokine gene expression was consistent with cytokine production, whereas in HIV-positive subjects it was not. The production of interferon-gamma in CCE-stimulated PBMC from both immunocompetent and HIV-positive subjects with cryptosporidiosis and the lack of interferon-gamma in CCE-stimulated PBMC from HIV-positive subjects without cryptosporidiosis indicate that C. parvum mainly induces a Th1 response.  (+info)

(4/3131) Cardiac autoimmunity in HIV related heart muscle disease.

OBJECTIVE: To assess the frequency of circulating cardiac specific autoantibodies in HIV positive patients with and without echocardiographic evidence of left ventricular dysfunction. SUBJECTS: 74 HIV positive patients including 28 with echocardiographic evidence of heart muscle disease, 52 HIV negative people at low risk of HIV infection, and 14 HIV negative drug users who had all undergone non-invasive cardiac assessment were studied along with a group of 200 healthy blood donors. RESULTS: Cardiac autoantibodies detected by indirect immunofluorescence (serum dilution 1/10) were more common in the HIV positive patients (15%), particularly the HIV heart muscle disease group (21%), than in HIV negative controls (3.5%) (both p < 0.001). By ELISA (dilution 1/320), abnormal anti-alpha myosin autoantibody concentrations were found more often in HIV patients with heart muscle disease (43%) than in HIV positive patients with normal hearts (19%) or in HIV negative controls (3%) (p < 0.05 and p < 0.001, respectively). Anti-alpha myosin autoantibody concentrations were greater in HIV positive patients than in HIV negative controls, regardless of cardiac status ((mean SD) 0.253 (0.155) v 0.170 (0.076); p = 0.003). In particular the mean antibody concentration was higher in the HIV heart muscle disease patients (0.291 (0.160) v 0.170 (0.076); p = 0.001) than in HIV negative controls. On follow up, six subjects with normal echocardiograms but raised autoantibody concentrations had died after a median of 298 days, three with left ventricular abnormalities at necropsy. This compared with a median survival of 536 days for 21 HIV positive patients with normal cardiological and immunological results. CONCLUSIONS: There is an increased frequency of circulating cardiac specific autoantibodies in HIV positive individuals, particularly those with heart muscle disease. The data support a role for cardiac autoimmunity in the pathogenesis of HIV related heart muscle disease, and suggest that cardiac autoantibodies may be markers of the development of left ventricular dysfunction in HIV positive patients with normal hearts.  (+info)

(5/3131) Voluntary newborn HIV-1 antibody testing: a successful model program for the identification of HIV-1-seropositive infants.

Harlem Hospital in New York City has one of the highest HIV-1 newborn seroprevalence rates in the United States. We report the results of a program introduced in 1993 and designed to identify HIV-1-seropositive (HIV+) newborns at birth. All new mothers, independent of risk, received HIV counseling that emphasized the medical imperative to know the infant's HIV status as well as their own. Consent was obtained to test the infant; discarded cord blood samples were tested by enzyme-linked immunosorbent assay (ELISA), and when positive, Western Blot confirmation. We compared the number of HIV+ infants identified through voluntary testing with the number reported by the anonymous New York State Newborn HIV Seroprevalence Study. In 1993, 97.8% (91 of 93) of the number of HIV+ infants identified by the anonymous testing were identified through voluntary maternal and newborn testing programs. Eighty-five HIV+ infants were identified before nursery discharge: 50% (42/85) through newborn testing; 14% (12/85) through prenatal testing; 13% (11/85) presented to care knowing their status; 23% (20/85) were known because of a previous HIV+ child. Six additional HIV+ children were diagnosed after hospital discharge (mean age, 5.5 months; range 1.5 through 17 months); four presented with symptomatic disease. The optimal time for identification of the HIV+ pregnant woman is before or during pregnancy, but when this does not occur, voluntary newborn testing can identify many HIV+ infants who would otherwise be discharged undiagnosed from the nursery.  (+info)

(6/3131) Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure.

A new test that measures interferon-gamma (IFN-gamma) release in whole blood following stimulation with tuberculin has the potential to detect tuberculosis infection using a single blood draw. The IFN-gamma release assay was compared with the standard tuberculin skin test (TST) among 467 intravenous drug users at risk for tuberculosis in urban Baltimore. Among 300 human immunodeficiency virus (HIV)-seronegative patients, the IFN-gamma release assay was positive in 177 (59%), whereas the TST was positive in 71 (24%), for a percent agreement of 59% (kappa=26%). Among 167 HIV-seropositive subjects, the IFN-gamma release assay identified 32 reactors (19%); the TST identified 16 reactors (9.6%), for a percent agreement of 82% (kappa=28%). The IFN-gamma release assay detected more reactors than did the TST, but its agreement with TST was weak. As the TST is an imperfect standard, further evaluation of the IFN-gamma release assay among uninfected persons and persons with culture-confirmed tuberculosis will be useful.  (+info)

(7/3131) Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts.

To assess possible differences in immune status, proportions and absolute numbers of subsets of CD4+ and CD8+ T cells were compared between HIV- healthy Ethiopians (n = 52) and HIV- Dutch (n = 60). Both proportions and absolute numbers of naive CD4+ and CD8+ T cells were found to be significantly reduced in HIV Ethiopians compared with HIV- Dutch subjects. Also, both proportions and absolute numbers of the effector CD8+ T cell population as well as the CD4+CD45RA-CD27- and CD8+CD45RA-CD27- T cell populations were increased in Ethiopians. Finally, both proportions and absolute numbers of CD4+ and CD8+ T cells expressing CD28 were significantly reduced in Ethiopians versus Dutch. In addition, the possible association between the described subsets and HIV status was studied by comparing the above 52 HIV- individuals with 32 HIV+ Ethiopians with CD4 counts > 200/microliter and/or no AIDS-defining conditions and 39 HIV+ Ethiopians with CD4 counts < 200/microliter or with AIDS-defining conditions. There was a gradual increase of activated CD4+ and CD8+ T cells, a decrease of CD8+ T cells expressing CD28 and a decrease of effector CD8+ T cells when moving from HIV- to AIDS. Furthermore, a decrease of naive CD8+ T cells and an increase of memory CD8+ T cells in AIDS patients were observed. These results suggest a generally and persistently activated immune system in HIV- Ethiopians. The potential consequences of this are discussed, in relation to HIV infection.  (+info)

(8/3131) Tissue specific HPV expression and downregulation of local immune responses in condylomas from HIV seropositive individuals.

OBJECTIVE: To study the effect of tissue specific human papillomavirus (HPV) expression and its effect on local immunity in condylomas from HIV positive individuals. METHODS: Biopsy specimens of eight penile and eight perianal condylomas from HIV seropositive individuals were analysed. Expression of viral genes (HIV-tat and HPV E7 and L1) was determined by RT-PCR. The status of local immunity also was determined by RT-PCR by measuring CD4, CD8, CD16, CD1a, HLA-DR, and HLA-B7 mRNA levels in the tissues. Differentiation was determined by measuring involucrin, keratinocyte transglutaminase, as well as cytokeratins 10, 16, and 17. Proliferation markers such as PCNA and c-myc were also determined. RESULTS: The transcription pattern of HPV in perianal condylomas, which preferentially expressed the early (E7) gene, was different from that of penile condylomas, which primarily expressed the late (L1) gene. This transcription pattern is in good correlation with the keratinisation and differentiation patterns of the two epithelia: perianal biopsies preferentially expressed K16 and K17 while penile warts mainly expressed K10, markers of parakeratotic and orthokeratotic epithelia, respectively. Perianal biopsies also showed a higher degree of proliferation (PCNA and c-myc). Interestingly, transcription of HIV-tat was also higher in perianal than in penile biopsies. A high degree of local immunodeficiency was observed in perianal biopsies--that is, levels of CD4, CD16, and CD1a mRNAs were significantly lower. A negative correlation between CD1a (Langerhans cells) levels and HPV E7 levels was established. HPV E7 levels positively correlated with HIV-tat levels. Perianal tissues demonstrated more CD1a depression and tat associated HPV upregulation. CONCLUSION: HIV influences the expression of HPV genes resulting in local immunosuppression that might lead to an inappropriate immune surveillance of viral infection. Also, tissue type is an important factor in controlling viral transcription in a differentiation dependent manner. These findings may explain the higher rate of dysplasia and neoplasia in the perianal area.  (+info)



patients


  • At Saint Francis Memorial Hospital, a team of plastic surgeons, infectious disease specialists, medical internists, psychiatrists, social workers, and nurses was established for the care of patients with burn injuries who have HIV. (ehesp.fr)
  • Of the remaining 100 consecutive patients, all consented to HIV testing. (ehesp.fr)
  • None of these patients, even those with known risk factors, was found to have undiagnosed HIV positivity. (ehesp.fr)
  • This information will be compared to that of HIV patients in another study. (clinicaltrials.gov)
  • The results from this study, using healthy volunteers, will be compared to those in another study of HIV-infected patients. (clinicaltrials.gov)
  • Numbers of phenotypically naive CD4+ cells (CD45RA+/CD62L+) are compared between healthy, HIV-seronegative volunteers and HIV-seropositive patients of A5015. (clinicaltrials.gov)
  • This is a phase II, multicenter, non-randomized, open-label study evaluating the combination of pemetrexed plus carboplatin in HIV-positive patients with lung cancer. (clinicaltrials.gov)
  • To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection. (clinicaltrials.gov)
  • To investigate whether topical HPMPC therapy can induce regression of condyloma acuminatum in patients with HIV infection. (clinicaltrials.gov)
  • The investigators are interested in understanding personal factors such as medical conditions and mental health, as well as social and economic factors, that influence marijuana (and other substance) use in HIV-positive patients. (clinicaltrials.gov)
  • Participants will be patients in the HIV clinic. (clinicaltrials.gov)
  • ln the present protocol we plan to perform a kinetic brain imaging study with [11C]PBR28 in HlV-seronegative controls, HIV-seropositive, non-impaired patients, and HlV-seropositive patients with minor cognitive motor disorder(MCMD). (clinicaltrials.gov)
  • Proleukin) as an immune adjuvant in HIV-seropositive patients. (clinicaltrials.gov)

seropositive


  • HIV-seropositive based on ELISA and Western blot (except the HIV-seronegative subjects, who will have ELISA screening). (clinicaltrials.gov)
  • HIV-seropositive, non-pregnant adults, aged 18 - 45 years old who have been on standard highly active antiretroviral therapy (HAART) for at least 6 months prior to enrollment or who have never started HAART regimen will be recruited in the study. (clinicaltrials.gov)
  • Male and female HIV seropositive adults aged 18 to 45 years old who have given the written informed consent. (clinicaltrials.gov)

infection


  • HIV infection in a patient with burn injuries complicates the care of both the patient and the treating burn team. (ehesp.fr)
  • Highly active antiretroviral therapy (HAART) has made a significant impact on the natural history of HIV-1 infection, but toxicities and complexities of therapy limit long-term efficacy, and make simpler yet effective HAART regimens highly desirable. (clinicaltrials.gov)
  • Have HIV infection. (clinicaltrials.gov)

AIDS


  • In the vast majority of those infected with HIV virus who are untreated, there is deterioration in immune health over a period of months or years inevitably leading to full-blown AIDS and demise. (clinicaltrials.gov)

conclude


  • We conclude that prevalence of HIV seropositivity is low in chronic diarrhea cases in this part of the country. (omicsonline.org)

antiretroviral


  • GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men. (clinicaltrials.gov)

Volunteers


  • Samples from these volunteers will serve as controls to those from the HIV-infected participants of A5015 (a comparison study of 2 age-differentiated cohorts to determine potential mechanisms that might contribute to accelerated HIV-disease progression that is associated with aging). (clinicaltrials.gov)

immune


  • The purpose of this study is to compare immune system activity in young people and older people who do not have HIV. (clinicaltrials.gov)
  • HIV also affects immune system activity. (clinicaltrials.gov)
  • This may provide information on immune system activity in aging and HIV. (clinicaltrials.gov)

ELISA


  • All samples were subjected to initial screening by the ELISA based test for detection of HIV antibodies. (omicsonline.org)

increases


  • In the patient, HIV slows wound healing and increases the complications seen with burns. (ehesp.fr)

participants


Study


  • The purposes of this study are to determine whether Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe for vaginal use. (clinicaltrials.gov)
  • This study is designed to show if Carraguard® can protect women against HIV if it is used before sex, and is safe for long-term use. (clinicaltrials.gov)

population


  • HIV seropositivity in a Burn Center's population. (ehesp.fr)

positive


  • Those found to be positive by history (3 of 103) were excluded from HIV testing. (ehesp.fr)
  • 50 copies/mL) over a 48-week treatment period in HIV-positive women and men. (clinicaltrials.gov)